Navitoclax
As of the edition of 20 October 2026, Navitoclax is a small molecule: in active development; acts on BCL2 and BCL2L1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 44, 8 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 4 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Navitoclax.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Navitoclax.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 22 | 15 | 5 | 2 |
| Phase 2 | 18 | 7 | 4 | 6 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 44 |